32 Our approach to value co-creation includes establishing and maintaining connections with our customers early in the drug discovery process. We seek to work with them end-to-end in every stage of drug development, from initial research to final production. We believe this approach provides our customers with the benefits of speed, cost and innovation through continuity and relatively faster transition through the various phases of drug development. During the discovery phase, having chemistry and biology capabilities enables efficient transfer of compounds for testing as well as quick feedback on the properties of each drug-like molecule to enable redesign of better molecules. Similarly, having discovery chemistry and process chemistry under one roof helps ensure that principles of scalable manufacturing are incorporated even at the pre-clinical stages, which reduces time taken to transition to clinical stages. Also, having process development and manufacturing within the same organization ensures that not only efficient chemistry is developed, but also ensures that the right equipment and manufacturing conditions for high volume commercial manufacturing are selected. Besides being a CRDMO, our internal processes and systems in science and technology, ESG and quality management, sustain co-creation efforts with our customers. Value co-creation with our customers in the innovation value chain 28 USFDA/ PMDA/ CDSCO 100 Serving 28 commercial APIs through 38 products and 10 Phase III APIs through 11 products Successful track record of regulatory approvals Products in various stage of development across pre-clinical. Phase I & Phase II clinical trial stages 280+ USA, UK, EU & JAPAN 18 of the top 25 Innovator pharmaceutical & biotech companies served Customer base is highly regulated market Largest pharmaceutical companies work with Sai
RkJQdWJsaXNoZXIy MTIwMDc4NQ==